Subject: JLD meeting with AMISA II, 26 Feb 2014

From: [ART. 4.1b]
Sent: Wednesday, February 26, 2014 5:03 PM
To: RATCH Signe (TRADE); SOURMEUS Petros (TRADE); LEVIE Damien (TRADE); PERREAU DE PINNINCK Fernando (TRADE); JESSEN Anders (TRADE); KONIG Helena (TRADE); NYMAN Jon (TRADE); LOBILLO BORRERO Cristina (TRADE); HANNONEN Marjut (CAB-DE GUICH)
Cc: HANNONEN Marjut (CAB-DE GUICH)

Subject: JLD meeting with AMISA II, 26 Feb 2014

Report: JLD meeting with AMISA II. At the request of AMISA II (a non-profit organisation that organises monthly meetings between high-level EU policy makers and industry), JLD met with a group of companies for a breakfast meeting this morning.

Participants: Google, [NOT RELEVANT]

The 10-15 minutes speech by JLD was followed by an interactive discussion of more than an hour. Main issues raised:

Several questions related to TTIP. Asked about the possible bridge between the different regulatory approaches on chemicals in the EU and the US, REACH and TSCA respectively, JLD replied that TTIP will try to find commonalities but always taking into account that TSCA and REACH are already well established in both countries. [NOT RELEVANT] enquired about government procurement prospects in TTIP. JLD replied that having an ambitious chapter on public procurement in the TTIP is a key objective for the EU. [NOT RELEVANT] asked IPR prospects and enforcement on TTIP. JLD indicated that even though negotiations depart from different IPR templates, certain commonalities will be explored, except for criminal sanctions. Asked about how the EU is handling transparency, JLD replied that the transparency with which TTIP negotiations are conducted is unprecedented. [NOT RELEVANT] enquired about the elimination of export restriction on oil and gas in the energy chapter and a possible agreement between the EU and the US on enforcing provisions on export restrictions with third countries. JLD replied that the elimination of export restrictions in TTIP should be bound. [NOT RELEVANT] enquired about the real approximation in regulatory approaches on pharma as this initiative has been already ongoing for more than 20 years. JLD indicated that GMP is an important element for the EU. Other questions related to ISDS, data flows, differences in regulation making, inclusion of financial services, and equity caps limitations.